Asset Publisher

null Esteban Martínez´s group


Our group has been working in this field since 1996 focused on two topics of research:

  1. Efficacy and tolerability of antiretroviral therapy  
  2. Epidemiology, prevention and management of non-AIDS events  

These two topics are partially related since the long-term tolerability of antiretroviral therapy may have an impact on the incidence and management of non-AIDS events and the risk for or the development of non-AIDS events may require to modify antiretroviral therapy for reasons other than virological failure.

Efficacy and tolerability of antiretroviral therapy
Our group has been involved in pivotal studies from more than 15 years including strategic trials of potent antiretroviral agents with different third drugs such as ATLANTIC study, CD4- and HIV RNA-guided therapy trials, and different switching studies in virologically suppressed patients aimed to improve the convenience or tolerability of antiretroviral therapy. We have developed studies assessing incidence and risk factors for specific adverse effects of antiretroviral agents such as Preotease inhibitor-associated dyslipidemia, nevirapine-associated hypersensitivity, or raltegravir-associated creatin kinase elevations. Some clinical studies have been done in collaboration with other Spanish and international centres, and in many instances we have coordinated the study from our institution. We aim to simplify antiretroviral therapy further developing tools to guarantee virological efficacy and to personalise therapy minimising the risk for adverse events.

Epidemiology, prevention and management of non-AIDS events  
Our group has been also involved in the epidemiology, prevention and management of non-AIDS events since these events gained increasing importance a few years ago. Together with members from the European AIDS Clinical Society (EACS) and also with other clinical research groups in Spain we have been involved in developing prevention and management guidelines and designing and participating into strategic studies aimed to decrease the risk of cardiovascular, kidney or bone disease in HIV-infected patients. We have created links with other research groups out of the field of HIV infection to better address these issues. We aim to know further the factors associated with a higher risk for developing non-AIDS events and to develop evidence-based strategies for their prevention and management.

Related Assets


Esteban Martínez
Polyana Monteiro

Related Assets

Related Assets


  • Endothelial function in HIV-infected patients switching from boosted protease inhibitors to raltegravir: a sub-study of the SPIRAL study. 
    Masia M, Martinez E, Padilla S, Gatell J, Gutierrez F.  J Antimicrob Chemother 2012 (accepted) 
  • CK elevation in HIV-1-infected patients receiving raltegravir-containing therapy: a cohort study. 
    Monteiro P, Perez I, Pich J, Gatell J, Martinez E.  J Antimicrob Chemother 2012 (accepted) 
  • Different contribution of smoking, diabetes, or hypertension to acute coronary syndrome between HIV-infected patients and uninfected adults. 
    Calvo M, Perello R, Perez I, Mateo M, Junyent M, Laguno M, Blanco JL, Martinez-Rebollar M, Sanchez M, Mallolas J, Gatell J, Martinez E.  HIV Med 2012 (accepted) 
  • Changes of cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. 
    Martinez E, D'Albuquerque PM, Llibre JM, et al.  AIDS 2012 (in press) 
  • LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. 
    Saumoy M, Sánchez-Quesada JL, Martínez E, et al.  Atherosclerosis 2012 (in press) 
  • Cardiovascular risk and human immunodeficiency virus infection. 
    Calvo M, Martínez E.  Enferm Infecc Microbiol Clin 2012 (in press) 
    Freitas P, Carvalho D, Santos AC, Madureira AJ, Xerinda S, Martinez E,et al.  J Clin Hypertens (Greenwich) 2012; 14: 593-600. 
  • Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. 
    Martínez E, d'Albuquerque PM, Pérez I, Pich J, Gatell JM.  AIDS Res Hum Retroviruses 2012 (in press) 
  • Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance. 
    Freitas P, Carvalho D, Santos AC, Mesquita J, Matos MJ, Madureira AJ, Martinez E, et al.  BMC Infect Dis 2012; 12: 180. 
  • Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. 
    Domingo P, Estrada V, López-Aldeguer J, Villaroya F, Martínez E.  AIDS Rev 2012; 14: 112-123. 

Related Assets